Skip to ContentSkip to Navigation
Research Pediatrics
University Medical Center Groningen

New Key Publication:Personalised modelling of clinical heterogeneity between medium-chain acyl-CoA dehydrogenase patients

04 September 2023

Background: Monogenetic inborn errors of metabolism cause a wide phenotypic heterogeneity that may even differ between family members carrying the same genetic variant. Computational modelling of metabolic networks may identify putative sources of this inter-patient heterogeneity. Here, we mainly focus on medium-chain acyl-CoA dehydrogenase deficiency (MCADD), the most common inborn error of the mitochondrial fatty acid oxidation (mFAO). It is an enigma why some MCADD patients-if untreated-are at risk to develop severe metabolic decompensations, whereas others remain asymptomatic throughout life. We hypothesised that an ability to maintain an increased free mitochondrial CoA (CoASH) and pathway flux might distinguish asymptomatic from symptomatic patients.

Results: We built and experimentally validated, for the first time, a kinetic model of the human liver mFAO. Metabolites were partitioned according to their water solubility between the bulk aqueous matrix and the inner membrane. Enzymes are also either membrane-bound or in the matrix. This metabolite partitioning is a novel model attribute and improved predictions. MCADD substantially reduced pathway flux and CoASH, the latter due to the sequestration of CoA as medium-chain acyl-CoA esters. Analysis of urine from MCADD patients obtained during a metabolic decompensation showed an accumulation of medium- and short-chain acylcarnitines, just like the acyl-CoA pool in the MCADD model. The model suggested some rescues that increased flux and CoASH, notably increasing short-chain acyl-CoA dehydrogenase (SCAD) levels. Proteome analysis of MCADD patient-derived fibroblasts indeed revealed elevated levels of SCAD in a patient with a clinically asymptomatic state. This is a rescue for MCADD that has not been explored before. Personalised models based on these proteomics data confirmed an increased pathway flux and CoASH in the model of an asymptomatic patient compared to those of symptomatic MCADD patients.

Conclusions: We present a detailed, validated kinetic model of mFAO in human liver, with solubility-dependent metabolite partitioning. Personalised modelling of individual patients provides a novel explanation for phenotypic heterogeneity among MCADD patients. Further development of personalised metabolic models is a promising direction to improve individualised risk assessment, management and monitoring for inborn errors of metabolism.

Authors:

  • Christoff Odendaal
  • Emmalie A Jager
  • Anne-Claire M F Martines
  • Marcel A Vieira-Lara
  • Nicolette C A Huijkman
  • Ligia A Kiyuna
  • Albert Gerding
  • Justina C Wolters
  • Rebecca Heiner-Fokkema
  • Karen van Eunen
  • Terry G J Derks
  • Barbara M Bakker

Read more BMC :https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-023-01652-9

Last modified:11 September 2023 09.37 a.m.

More news

  • 21 May 2024

    Results of 2024 University elections

    The votes have been counted and the results of the University elections are in!

  • 13 May 2024

    Trapping molecules

    In his laboratory, physicist Steven Hoekstra is building an experimental set-up made of two parts: one that produces barium fluoride molecules, and a second part that traps the molecules and brings them to an almost complete standstill so they can...

  • 29 April 2024

    Tactile sensors

    Every two weeks, UG Makers puts the spotlight on a researcher who has created something tangible, ranging from homemade measuring equipment for academic research to small or larger products that can change our daily lives. That is how UG...